Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Get Free Report) dropped 3.8% during trading on Monday . The company traded as low as $1.50 and last traded at $1.54. Approximately 145,282 shares were traded during trading, a decline of 96% from the average daily volume of 3,256,301 shares. The stock had previously closed at $1.60.
Scinai Immunotherapeutics Trading Down 3.8%
The firm has a market capitalization of $1.54 million, a P/E ratio of -0.16 and a beta of 1.86. The stock’s 50-day simple moving average is $1.99 and its two-hundred day simple moving average is $2.55. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.32 and a quick ratio of 1.32.
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
Featured Stories
- Five stocks we like better than Scinai Immunotherapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Biotech Catalysts Present Major Opportunity
- What is a Special Dividend?
- 3 Cheap Stocks That Shouldn’t Be This Low
- What is a Bond Market Holiday? How to Invest and Trade
- Why Sprouts Farmers Market is Buying $1 Billion of Its Own Stock
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
